Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN78973763
ISRCTN78973763
Completed
Not Applicable

Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy

Shanghai Proton and Heavy Ion Center0 sites31 target enrollmentAugust 14, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-small cell lung cancer (NSCLC)CancerNon-small cell lung cancer (NSCLC)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
on-small cell lung cancer (NSCLC)
Sponsor
Shanghai Proton and Heavy Ion Center
Enrollment
31
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/30683133

Registry
who.int
Start Date
August 14, 2018
End Date
July 31, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Shanghai Proton and Heavy Ion Center

Eligibility Criteria

Inclusion Criteria

  • •1\. Non\-small cell lung cancer (NSCLC):
  • •1\.1\. According to the following criteria of the American Association of Cancer staging version 7:
  • •1\.1\.1\. T1\-2 (T1 indicates that the cancer is contained within the lungs and T2 indicates that either the cancer is 3\-5 cm in size, or any of the following: the cancer involves the main airway but is not close to where the bronchus divides, the cancer involves the inner lining of the chest cavity, or that part/all of the lung has collapsed or is blocked)
  • •1\.1\.2\. N0\-1 (N0 indicates no spread to lymph nodes, N1 indicates there are cancer cells in the lymph nodes)
  • •1\.1\.3\. M0 (no distant cancer spread found)
  • •1\.2\. Medically inoperable or declined surgery
  • •2\. Longest diameters of primary tumour and hilar lymph node \<5 cm
  • •3\. Pathologically confirmed NSCLC or clinically diagnosed as NSCLC with the Fluorodeoxyglucose\-Positron Emission Tomography/Computed Tomography (FDG\-PET/CT) avid lung lesion
  • •4\. Diagnosed with NSCLC with CT scans by 2 senior radiologists independently

Exclusion Criteria

  • •1\. Locally advanced or metastastic NSCLC at diagnosis
  • •2\. Previously received radiotherapy
  • •3\. Younger than 14 years of age
  • •4\. No signed informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Designing information for lung cancer patients in decision making.Patients presenting with a stage I non-small cell lung cancer (NSCLC).Patienten met stadium I niet kleincellige longkanker.
NL-OMON2116225
Completed
Not Applicable
tritional Assessment in Non-small Cell lung cancer patientslungcancerNon Small Cell Lung Cancer10038666
NL-OMON50451Antoni van Leeuwenhoek Ziekenhuis100
Completed
Not Applicable
Streamlining Staging of Lung cancer with Whole Body MRI
ISRCTN50436483niversity College London (UK)353
Completed
Phase 2
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerNon Small Cell Lung Cancer
NCT02716311Intergroupe Francophone de Cancerologie Thoracique118
Active, not recruiting
Phase 1
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Bayer370